Bank spots risk for slower Novo Nordisk restoration of Wegovy supply
A subsupplier to Novo Nordisk has run afoul of the FDA – again – and Jefferies thinks this might impact the Danish drugmaker’s planned relaunch of the obesity medicine.
by marketwire, translated by daniel pedersen
Necessary efforts to regain compliance for Novo Nordisk’s supplier, Catalent, might increase the risk that the Danish drugmaker won’t be able to secure a robust delivery of obesity drug Wegovy before the end of the year, assesses US-based investment bank Jefferies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk supplier gets another FDA warning
For subscribers
Analysts: Novo Nordisk's Wegovy relaunch must go smoothly
For subscribers
